Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nonacog Alfa Deemed Safe and Effective in Hemophilia B

Publish date:: July 3, 2019

Key clinical point: Real-world data shows that the recombinant factor IX product nonacog alfa is safe and effective for patients with hemophilia B.

Major finding: Effectiveness rates were 95.5% and 93.7% for patients who received routine prophylaxis and on-demand treatment, respectively.

Study details: A postmarketing surveillance study of 312 patients with hemophilia B.

Disclosures: The study was funded and conducted by Pfizer Japan. The authors reported financial relationships with Pfizer and several other companies. One coauthor is an employee of Pfizer Japan.

Citation:

Fukutake K et al. Haemophilia. 2019 Jun 6. doi: 10.1111/hae.13783

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,